Lipoprotein(a) was significantly reduced in patients treated with evolocumab, and those with the highest levels at baseline had the greatest benefit from this PCSK9 inhibitor, according to data ...
Armed with positive results in two phase 3 trials, MSD is poised to be the first drugmaker to file for approval of an oral PCSK9 inhibitor for lowering cholesterol. Top-line results from the CORALreef ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback